The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Generic Drugs-Global Market Insights and Sales Trends 2025
Synopsis
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
The global Generic Drugs market size is expected to reach US$ 551330 million by 2029, growing at a CAGR of 8.3% from 2023 to 2029. The market is mainly driven by the significant applications of Generic Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Generic Drugs market. Prescription, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Prescription Drugs segment is estimated at % CAGR for the next seven-year period.
Market competition is not intense. Teva, Novartis – Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.
North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Generic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Generic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Generic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Generic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Generic Drugs covered in this report include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc.
The global Generic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Global Generic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Generic Drugs market, Segment by Type:
Prescription
Non-Prescription Drugs
Global Generic Drugs market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Generic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
The global Generic Drugs market size is expected to reach US$ 551330 million by 2029, growing at a CAGR of 8.3% from 2023 to 2029. The market is mainly driven by the significant applications of Generic Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Generic Drugs market. Prescription, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Prescription Drugs segment is estimated at % CAGR for the next seven-year period.
Market competition is not intense. Teva, Novartis – Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.
North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Generic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Generic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Generic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Generic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Generic Drugs covered in this report include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc.
The global Generic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Global Generic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Generic Drugs market, Segment by Type:
Prescription
Non-Prescription Drugs
Global Generic Drugs market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Generic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Generic Drugs
1.1 Generic Drugs Market Overview
1.1.1 Generic Drugs Product Scope
1.1.2 Generic Drugs Market Status and Outlook
1.2 Global Generic Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Generic Drugs Market Size by Region (2018-2029)
1.4 Global Generic Drugs Historic Market Size by Region (2018-2023)
1.5 Global Generic Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Generic Drugs Market Size (2018-2029)
1.6.1 North America Generic Drugs Market Size (2018-2029)
1.6.2 Europe Generic Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Generic Drugs Market Size (2018-2029)
1.6.4 Latin America Generic Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Generic Drugs Market Size (2018-2029)
2 Generic Drugs Market by Type
2.1 Introduction
2.1.1 Prescription
2.1.2 Non-Prescription Drugs
2.2 Global Generic Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Generic Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Generic Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Generic Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Generic Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Generic Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Generic Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Generic Drugs Revenue Breakdown by Type (2018-2029)
3 Generic Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Generic Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Generic Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Generic Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Generic Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Generic Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Generic Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Generic Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Generic Drugs Revenue Breakdown by Application (2018-2029)
4 Generic Drugs Competition Analysis by Players
4.1 Global Generic Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Generic Drugs as of 2022)
4.3 Date of Key Players Enter into Generic Drugs Market
4.4 Global Top Players Generic Drugs Headquarters and Area Served
4.5 Key Players Generic Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Generic Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Teva
5.1.1 Teva Profile
5.1.2 Teva Main Business
5.1.3 Teva Generic Drugs Products, Services and Solutions
5.1.4 Teva Generic Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Teva Recent Developments
5.2 Novartis - Sandoz
5.2.1 Novartis - Sandoz Profile
5.2.2 Novartis - Sandoz Main Business
5.2.3 Novartis - Sandoz Generic Drugs Products, Services and Solutions
5.2.4 Novartis - Sandoz Generic Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis - Sandoz Recent Developments
5.3 Mylan
5.3.1 Mylan Profile
5.3.2 Mylan Main Business
5.3.3 Mylan Generic Drugs Products, Services and Solutions
5.3.4 Mylan Generic Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Sun Pharmaceutical Recent Developments
5.4 Sun Pharmaceutical
5.4.1 Sun Pharmaceutical Profile
5.4.2 Sun Pharmaceutical Main Business
5.4.3 Sun Pharmaceutical Generic Drugs Products, Services and Solutions
5.4.4 Sun Pharmaceutical Generic Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Sun Pharmaceutical Recent Developments
5.5 Aspen
5.5.1 Aspen Profile
5.5.2 Aspen Main Business
5.5.3 Aspen Generic Drugs Products, Services and Solutions
5.5.4 Aspen Generic Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Aspen Recent Developments
5.6 Fresenius Kabi
5.6.1 Fresenius Kabi Profile
5.6.2 Fresenius Kabi Main Business
5.6.3 Fresenius Kabi Generic Drugs Products, Services and Solutions
5.6.4 Fresenius Kabi Generic Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Fresenius Kabi Recent Developments
5.7 Pfizer (Hospira)
5.7.1 Pfizer (Hospira) Profile
5.7.2 Pfizer (Hospira) Main Business
5.7.3 Pfizer (Hospira) Generic Drugs Products, Services and Solutions
5.7.4 Pfizer (Hospira) Generic Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer (Hospira) Recent Developments
5.8 Sanofi
5.8.1 Sanofi Profile
5.8.2 Sanofi Main Business
5.8.3 Sanofi Generic Drugs Products, Services and Solutions
5.8.4 Sanofi Generic Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Sanofi Recent Developments
5.9 Aurobindo
5.9.1 Aurobindo Profile
5.9.2 Aurobindo Main Business
5.9.3 Aurobindo Generic Drugs Products, Services and Solutions
5.9.4 Aurobindo Generic Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Aurobindo Recent Developments
5.10 Lupin
5.10.1 Lupin Profile
5.10.2 Lupin Main Business
5.10.3 Lupin Generic Drugs Products, Services and Solutions
5.10.4 Lupin Generic Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Lupin Recent Developments
5.11 Dr. Reddy's
5.11.1 Dr. Reddy's Profile
5.11.2 Dr. Reddy's Main Business
5.11.3 Dr. Reddy's Generic Drugs Products, Services and Solutions
5.11.4 Dr. Reddy's Generic Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Dr. Reddy's Recent Developments
5.12 Apotex
5.12.1 Apotex Profile
5.12.2 Apotex Main Business
5.12.3 Apotex Generic Drugs Products, Services and Solutions
5.12.4 Apotex Generic Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Apotex Recent Developments
5.13 Cipla
5.13.1 Cipla Profile
5.13.2 Cipla Main Business
5.13.3 Cipla Generic Drugs Products, Services and Solutions
5.13.4 Cipla Generic Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Cipla Recent Developments
5.14 ENDO (Par Pharmaceutical)
5.14.1 ENDO (Par Pharmaceutical) Profile
5.14.2 ENDO (Par Pharmaceutical) Main Business
5.14.3 ENDO (Par Pharmaceutical) Generic Drugs Products, Services and Solutions
5.14.4 ENDO (Par Pharmaceutical) Generic Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 ENDO (Par Pharmaceutical) Recent Developments
5.15 Stada Arzneimittel
5.15.1 Stada Arzneimittel Profile
5.15.2 Stada Arzneimittel Main Business
5.15.3 Stada Arzneimittel Generic Drugs Products, Services and Solutions
5.15.4 Stada Arzneimittel Generic Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Stada Arzneimittel Recent Developments
5.16 Krka Group
5.16.1 Krka Group Profile
5.16.2 Krka Group Main Business
5.16.3 Krka Group Generic Drugs Products, Services and Solutions
5.16.4 Krka Group Generic Drugs Revenue (US$ Million) & (2018-2023)
5.16.5 Krka Group Recent Developments
5.17 Nichi-Iko Pharmaceutical
5.17.1 Nichi-Iko Pharmaceutical Profile
5.17.2 Nichi-Iko Pharmaceutical Main Business
5.17.3 Nichi-Iko Pharmaceutical Generic Drugs Products, Services and Solutions
5.17.4 Nichi-Iko Pharmaceutical Generic Drugs Revenue (US$ Million) & (2018-2023)
5.17.5 Nichi-Iko Pharmaceutical Recent Developments
5.18 Valeant
5.18.1 Valeant Profile
5.18.2 Valeant Main Business
5.18.3 Valeant Generic Drugs Products, Services and Solutions
5.18.4 Valeant Generic Drugs Revenue (US$ Million) & (2018-2023)
5.18.5 Valeant Recent Developments
5.19 Zydus Cadila
5.19.1 Zydus Cadila Profile
5.19.2 Zydus Cadila Main Business
5.19.3 Zydus Cadila Generic Drugs Products, Services and Solutions
5.19.4 Zydus Cadila Generic Drugs Revenue (US$ Million) & (2018-2023)
5.19.5 Zydus Cadila Recent Developments
5.20 Hikma
5.20.1 Hikma Profile
5.20.2 Hikma Main Business
5.20.3 Hikma Generic Drugs Products, Services and Solutions
5.20.4 Hikma Generic Drugs Revenue (US$ Million) & (2018-2023)
5.20.5 Hikma Recent Developments
5.21 Pharmaniaga Berhad
5.21.1 Pharmaniaga Berhad Profile
5.21.2 Pharmaniaga Berhad Main Business
5.21.3 Pharmaniaga Berhad Generic Drugs Products, Services and Solutions
5.21.4 Pharmaniaga Berhad Generic Drugs Revenue (US$ Million) & (2018-2023)
5.21.5 Pharmaniaga Berhad Recent Developments
5.22 Hovid Berhad
5.22.1 Hovid Berhad Profile
5.22.2 Hovid Berhad Main Business
5.22.3 Hovid Berhad Generic Drugs Products, Services and Solutions
5.22.4 Hovid Berhad Generic Drugs Revenue (US$ Million) & (2018-2023)
5.22.5 Hovid Berhad Recent Developments
5.23 Duopharma Biotech
5.23.1 Duopharma Biotech Profile
5.23.2 Duopharma Biotech Main Business
5.23.3 Duopharma Biotech Generic Drugs Products, Services and Solutions
5.23.4 Duopharma Biotech Generic Drugs Revenue (US$ Million) & (2018-2023)
5.23.5 Duopharma Biotech Recent Developments
5.24 Kotra Pharma
5.24.1 Kotra Pharma Profile
5.24.2 Kotra Pharma Main Business
5.24.3 Kotra Pharma Generic Drugs Products, Services and Solutions
5.24.4 Kotra Pharma Generic Drugs Revenue (US$ Million) & (2018-2023)
5.24.5 Kotra Pharma Recent Developments
5.25 HOE Pharmaceutical
5.25.1 HOE Pharmaceutical Profile
5.25.2 HOE Pharmaceutical Main Business
5.25.3 HOE Pharmaceutical Generic Drugs Products, Services and Solutions
5.25.4 HOE Pharmaceutical Generic Drugs Revenue (US$ Million) & (2018-2023)
5.25.5 HOE Pharmaceutical Recent Developments
5.26 Y.S.P. Industries
5.26.1 Y.S.P. Industries Profile
5.26.2 Y.S.P. Industries Main Business
5.26.3 Y.S.P. Industries Generic Drugs Products, Services and Solutions
5.26.4 Y.S.P. Industries Generic Drugs Revenue (US$ Million) & (2018-2023)
5.26.5 Y.S.P. Industries Recent Developments
6 North America
6.1 North America Generic Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Generic Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Generic Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Generic Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Generic Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Generic Drugs Market Dynamics
11.1 Generic Drugs Industry Trends
11.2 Generic Drugs Market Drivers
11.3 Generic Drugs Market Challenges
11.4 Generic Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
